Emerging biological therapies for pancreatic carcinoma

European Journal of Surgical Oncology

Volumn 28, Issue 4, 2002, Pages 370-378

  Gilliam, Andrew D ^a   Watson, Susan A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Molecular biology; Pancreatic cancer; Therapy

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ADENOVIRUS VECTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FLUOROURACIL; FLUTAMIDE; GANCICLOVIR; GASTRIN ANTAGONIST; GEMCITABINE; IMATINIB; ISIS 2503; LONAFARNIB; MATRIX METALLOPROTEINASE INHIBITOR; METHIONINE GAMMA LYASE; MONOCLONAL ANTIBODY; ONYX 015; PRODRUG; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; SELENOMETHIONINE; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; TIPIFARNIB; TUMOR VACCINE; UNINDEXED DRUG; VATALANIB;

ARTHRALGIA; ARTHRITIS; BIBLIOGRAPHIC DATABASE; BIOLOGICAL THERAPY; BIOTECHNOLOGY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HUMAN; JOINT STIFFNESS; MANIPULATIVE MEDICINE; MEDICAL LITERATURE; MEDLINE; NEUTROPENIA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PUBLICATION; REVIEW; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM;

EID: 0036620226     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2001.1248     Document Type: Review

References (105)

1. Parkin DM, Muir CS, Whelan SL et al. Cancer Incidence in Five Continents. Vol. 6. IARC Scientific Publication 120. Lyon: International Agency for Research on Cancer, 1992.
2. Fernandez E, Lavecchia C, Porta M et al. Trends in pancreatic cancer mortality in Europe, 1985-1995. Int J Cancer 1994; 57: 786-92.
3. Bramhall SR, Neoptolemos JP, Stamp GWH, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997; 182: 347-55.
4. Gudjonson B. Cancer of the pancreas. Fifty years of surgery. Cancer 1987; 9: 2284-303.
5. Cause: Review of the Registrar General on Deaths by Cause, Sex and Age, in England and Wales. Office of Population Censuses and Surveys: Mortality statistics. Series DH2, No. 19. London: HMSO, 1992.
6. Carter DC. Cancer of the pancreas. Gut 1990; 31: 494-6.
7. Fontham ETH, Correa P. Epidemiology of pancreatic cancer. Surg Clin North Am 1989; 69: 551-67.
8. Boyle P, Hsieh CC, Maisonneuve P et al. Epidemiology of pancreas cancer. Int J Pancreat 1989; 5: 327-46.
9. Michaud DS, Giovannucci E, Willett WC et al. Physical activity, obesity, height, and the risk of pancreatic cancer. J Am Med Assoc 2001; 286(8): 921-9.
10. Bramhall SR, Allum WH, Jones AG et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease in the West Midlands: an epidemiological study. Br J Surg 1995; 82: 111-5.
11. Cancer Registry of Norway. Survival of Cancer Patients. Cases Diagnosed in Norway 1968-75. Oslo: Cancer Registry of Norway, 1980.
12. Brennan MF, Kinsella TJ, Casper ES. Cancer of the pancreas. In: De Vita VT Jr, Hellman S, Rosenburg SA (eds) Cancer. Principles and Practice of Oncology (4th edn). Vol. 3. Philadelphia, PA: Lippincott, 1993: 849-82.
13. Carmichael J. Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine. Digestion 1997; 58: 503-7.
14. Burris HA, Moore MJ, Anderson J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomised trial. J Clin Oncol 1997; 15: 2403-13.
15. Hidalgo M, Castellano D, Paz-Ares L et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17(2): 585-92.
16. Manu M, Buckels J, Bramhall S. Molecular technology and pancreatic cancer. Br J Surg 2000; 87(7): 840-53.
17. Lersch C, Van Cutsem E, Amado R et al. Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. J Clin Oncol 2001; 20: 608.
18. Camacho LH, Soignet SL, Pezzulli S et al. Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors. J Clin Oncol 2001; 20: 311.
19. Voi M, Tabernero J, Cooper MR et al. A phase I study of the farnesyltransferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients (pts) with advanced solid tumors: clinical findings. J Clin Oncol 2001; 20: 312.
20. Kim KB, Shin DM, Summey CC et al. Phase I study of farnesyl transferase inhibitor, BMS-214662 in solid tumors. J Clin Oncol 2001; 20: 313.
21. Bailey HH, Marnocha R, Arzoomanian R et al. Phase I trial of weekly paclitaxel and BMS214662 in patients with advanced solid tumors. J Clin Oncol 2001; 20: 314.
22. Mackay HJ, Hoekstra R, Eskens F et al. A phase I dose escalating study of BMS-214662 in combination with cisplatin (C) in patients with advanced solid tumours. J Clin Oncol 2001; 20: 315.
23. Holden SN, Eckhardt SG, Fisher S et al. A phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (PTS) with advanced solid malignancies. J Clin Oncol 2001; 20: 316.
24. Nakagawa K, Yamamoto N, Nishio K et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the farnesyl transferase inhibitor (FTI) R115777 in Japanese patients with advanced non-hematological malignancies. J Clin Oncol 2001; 20: 317.
25. Piccart-Gebhart MJ, Branle F, de Valeriola D et al. A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel: a promising combination in patients (PTS) with solid tumors. J Clin Oncol 2001; 20: 318.
26. Verweij J, Kehrer DFS, Planting AST et al. Phase I trial of irinotecan in combination with farnesyl transferase inhibitor (FTI) R115777. J Clin Oncol 2001; 20: 319.
27. Adjei AA, Erlichman C, Marks RS et al. A phase I trial of the farnesyltransferase inhibitor R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer. J Clin Oncol 2001; 20: 320.
28. Liebes L, Hochster H, Speyer J et al. Enhanced myelosuppression of topotecan when combined with the farnesyl transferase inhibitor, R115777: a phase I and pharmacodynamic study. J Clin Oncol 2001; 20: 321.
29. Schwartz G, Rowinsky EK, Rha SY et al. A phase I, pharmacokinetic and biologic correlative study of R115777 and trastuzumab (herceptin) in patients with advanced cancer. J Clin Oncol 2001; 20: 322.
30. Fischer T, Beck J, Petersen V et al. A phase I and pharmacokinetic trial of PKC412, an inhibitor of protein kinase C, in combination with taxol and carboplatin in patients with advanced NSCLC. J Clin Oncol 2001; 20: 1322.
31. Zonder JA, Karanes C, Brandt H et al. Myelosuppression and cytogenetic responses to STI-571, an inhibitor of the Bcr-Abl tyrosine kinase, in patients with chronic phase Cml. J Clin Oncol 2001; 20: 1224.
32. Reckmann AH, Fischer T, Peng B et al. Effect of food on ST1571 GLivec pharmacokinetics and bioavailability. J Clin Oncol 2001; 20: 1223.
33. Aghajanian C, Soignet S, Dizon DS et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. J Clin Oncol 2001; 20: 338.
34. Nix D, Pien C, Newman R et al. Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. J Clin Oncol 2001; 20: 339.
35. Wood JM, Bold G, Buchdunger E et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60(8): 2178-89.
36. Thomas A, Morgan B, Drevs J et al. Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase I studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. J Clin Oncol 2001; 20: 279.
37. Yang L, Hwang R, Pandit L et al. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg 1996; 224: 405-14.
38. Aoki K, Yoshida T, Matsumoto N et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8: 1105-13.
39. Heise C, Sampson-Johannes A, Williams A et al. ONYX-015, an EIB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3(6): 639-45.
40. Kirn H, Khuri F, Ganly I et al. A phase II trial of ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. J Clin Oncol 1999; 18: 1505.
41. Hao D, Rowinsky EK, Smetzer LA et al. A phase I and pharmacokinetic study of intravenous (IV) p53 gene therapy with RPR/INGN-201 in patients with advanced cancer. J Clin Oncol 2001; 20: 1045.
42. Muller CY, Coleman RL, Rogers P et al. Phase I intraperitoneal adenoviral p53 gene transfer in ovarian cancer. J Clin Oncol 2001; 20: 1025.
43. Yver A, Gautier E, Saulnier P et al. Clinical biosafety, distribution, genetic stability and potential for transmission of adenoviral vector for gene transfer (therapy): data from 190 subjects treated intra-tumorally with RPR/INGN 201 (Ad5CMV-p53). J Clin Oncol 2001; 20: 1046.
44. Reid TR, Galanis E, Abbruzzese J et al. Intra-arterial administration of a replication-selective adenovirus Ci-1042 (Onyx-015) in patients with colorectal carcinoma metastatic to the liver: safety, feasibility and biological activity. J Clin Oncol 2001; 20: 549.
45. Espinosa E, Casado E, Navarro JG et al. Drug induced transcriptional modulation for cancer gene therapy. J Clin Oncol 2001; 20: 2628.
46. Ashton WT, Karkas JD, Field AK et al. Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′NDG). Biochem Biophys Res Commun 1982; 108: 1716-21.
47. Hoffman RM, Miki K, Gupta A et al. Combination methioninase-gene/selenomethionine prodrug cancer gene-therapy induces Bcl-2-independent apoptosis. J Clin Oncol 2001; 20: 1041.
48. Friedlos F, Court S, Ford M et al. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther 1998; 5: 105-12.
49. Jaffee EM, Dranoff G, Cohen LK et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993; 53(S10): 2221-6.
50. DiMaio JM, Clary BM, Via DF et al. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994; 116: 205-13.
51. Perez RP, Smith JW III, Alberts SR et al. Phase II trials of ISIS 2503, an antisense inhibitor of H-ras, in patients (pts) with advanced pancreatic carcinoma (CA). J Clin Oncol 2001; 20: 628.
52. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55: 3810-6.
53. Gress TM, Muller-Pillasch F, Lerch MM et al. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407-13.
54. Evans J, Bramhall S, Carmichael J et al. A phase II study of marimastat in advanced pancreatic cancer. Ann Oncol 1996; 7: 239.
55. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat Pancreatic Cancer Study Group. Marimastat as firstline therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19(15): 3447-55.
56. Gupta E, Huang M, Mao Y et al. Pharmacokinetic (PK) evaluation of BMS-275291, a matrix metalloproteinase (MMP) inhibitor, in cancer patients. J Clin Oncol 2001; 20: 301.
57. Daniels R, Gupta E, Kollia G et al. Safety and pharmacokinetics of BMS-275291, a novel matrix metalloproteinase inhibitor in healthy subjects. J Clin Oncol 2001; 20: 395.
58. Hurwitz H, Humphrey J, Williams K et al. A phase I trial of BMS-275291: a novel, non-hydroxamate, sheddase-sparing matrix metalloproteinase inhibitor (MMP) with no dose-limiting arthritis. J Clin Oncol 2001; 20: 387.
59. Franqois B, Champagne P, Evans WK et al. Phase I/II trials on the safety, tolerability and efficacy of Æ-941 (neovastat) in patients with solid tumors. J Clin Oncol 2001; 20: 2861.
60. Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1991; 173: 273-6.
61. Fossum B, Gedde-Dahl T III, Breivik J et al. p21-ras-peptide-specific, T-cell responses in a patients with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly→Asp). Int J Cancer 1994; 56:40-5.
62. Chang KJ, Nguyen PT Thompson JA et al. Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound-guided fine-needle injection in patients with advanced pancreatic carcinoma. Cancer 2000; 88(6): 1325-35.
63. Sharma P, Kumar A, Batni S, Chauhan VS. Co-dominant and reciprocal T-helper cell activity of epitopic sequences and formation of junctional B-cell determinants in synthetic T:B chimeric immunogens. Vaccine 1993; 11 (13): 1321-6.
64. Moviglia G, Iraola N, Hisserodt J et al. Combination immunotherapy for pancreatic cancer. J Clin Oncol 2001; 20: 1052.
65. Jayson GC, Mulatero C, Ranson M et al. Anti-VEGF antibody HuMV833: an EORTC Biological Treatment Development group phase I toxicity, pharmacokinetic and pharmacodynamic study. J Clin Oncol 2001; 20: 14.
66. Bruns CJ, Harbison MT, Davis DW et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 65(5): 1936-48.
67. Abbruzzese JL, Rosenberg A, Xiong O et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001; 20: 518.
68. Sawada T, Nishihara T, Yamashita Y et al. Targeting immunotherapy by chimeric monoclonal antibody Nd2 directed against pancreatic cancer mucin. J Clin Oncol 2001; 20: 1100.
69. Detjen KM, Farwig K, Welzel M et al. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-I dependent induction of apoptosis. Gut 2001; 49(2): 251-62.
70. Parihar R, Nadella P, Jensen R et al. A phase I trial of herceptin and interleukin-12 in patients with HER2-overexpressing malignancies. J Clin Oncol 2001; 20: 1031.
71. Iversen P, Marshall J, Blanke C et al. Active specific immunotherapy with a b-hCG peptide vaccine in patients with pancreatic cancer. J Clin Oncol 2001; 20: 1083.
72. Deckert PM, Welt S, Old LJ et al. Multi-targeted antifolate-phenylalanine: a novel prodrug for anti body-directed enzyme prodrug therapy. J Clin Oncol 2001; 20: 2098.
73. Piemonti L, Monti P, Zerbi A et al. Generation and functional characterisation of dendritic cells from patients with pancreatic carcinoma with special regard to clinical applicability. Cancer Immunol Immunother 2000; 49(10): 544-50.
74. Kobari M, Egawa S, Shibuya K et al. Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. Br J Surg 2000; 87(1): 43-8.
75. Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 2000; 275(43): 33951-6.
76. Saha D, Datta PK, Sheng H et al. Synergistic induction of transforming growth factor beta I and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia 1999; 1(6): 508-17.
77. Sawaoka H, Tsuji S, Tsuji M et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumour growth in vivo. Lab Invest 1999; 79(12): 1469-77.
78. Steibach G, Lynch PM, Philips RKS et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
79. Kokawa A, Kondo H, Gotoda T et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001; 91(2): 333-8.
80. Targarona EM, Pons MD, Gonzalez G et al. Is exocrine pancreatic cancer a hormone-dependent tumor? A study of the existence of sex hormone receptors in normal and neoplastic pancreas. Hepatogastroenterology 1991; 38(2): 165-9.
81. Andren-Sandberg A, Johansson J. Influence of sex hormones on pancreatic cancer. Int J Pancreatol 1990; 7(1-3): 167-76.
82. Corbishley TP, Iqbal MJ, Wilkinson ML, Williams R. Androgen receptor in human normal and malignant pancreatic tissue and cell lines. Cancer 1986; 57(10): 1992-5.
83. Greenaway B, Iqbal MJ, Johnson PJ, Williams R. Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J (Clin Res Edn) 1981; 283(6294): 751-3.
84. Greenaway BA. Androgen receptor-blocking agents: potential role in pancreatic cancer. Drugs Aging 2000; 17(3): 161-3.
85. Mayer A, Shaw J, D'Ath S et al. Gemcitabine and flutamide in advanced pancreatic cancer - a phase II study. J Clin Oncol 2001; 20: 2297.
86. Horimi T, Takasaki M, Toki A et al. The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas. Hepatogastroenterology 1996; 43(11): 1225-9.
87. Zalatnai A, Szegedi Z, Bocsi J. Flow cytometric evidence of apoptosis in human pancreatic cancer xenografts treated with sandosta (octreotide). Anticancer Res 2000; 20(3A): 1663-6.
88. Fisher WE, Muscarella P, O'Dorisio TM et al. Expression of the somatostatin receptor subtype-2 predicts response of human pancreatic cancer to octreotide. Surgery 1996; 120(2): 234-40.
89. Gillespie J, Poston GJ, Schachter M, Guillou PJ. Human pancreatic cancer cell lines do not express receptors for somatostatin. Br J Cancer 1992; 66(3): 483-7.
90. Sulkowski U, Buchler M, Pederzoli P et al. A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma. Eur J Cancer 1999; 35(13): 1805-8.
91. Rosenberg L, Barkun AN, Denis MH, Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995; 75(1): 23-8.
92. Wender FA, Zieren HU, Jacobi CA, Muller JM. Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen. Langebecks Arch Chir Suppl Kongressbd, 1998; 115: 1348-50.
93. Johnson LR. Regulation of gastrointestinal growth. In: Johnson LR, Christensen J, Grossman MI, Jacobson ED, Schultz SG (eds) Physiology of the Gastrointestinal Tract. New York: Raven, 1981: 169-96.
94. Townsend CM Jr, Beauchamp RD, Singh P, Thompson JC. Growth factors and intestinal neoplasms. Am J Surg 1988; 155: 526-36.
95. Watson SA, Durrant LG, Crosbie JD, Morris DL. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin. Int J Cancer 1989; 43: 692-6.
96. Smith JP, Fantaskey AP, Liu G, Zagon IS. Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol 1995; 268: R135-41.
97. Roebuck BID, Baumgartner KJ, Longnecker DS. Growth of pancreatic foci and development of pancreatic cancer with a single dose of azaserine in the rat. Carcinogenesis 1987; 8: 1831-5.
98. Tang G, Biemond I, Offerhaus GJA, Verspaget W, Lamers CBHW. Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumour-free pancreas. Br J Cancer 1997; 75: 1467-73.
99. de Weerth A, von Schrenck T, Lohr M et al. Human pancreatic cancer cell lines express the CCKB receptor. Hepatogastroenterology 1999; 46: 472-8.
100. Smith IP, Hamory MW, Verderame MF, Zagon IS. Quantitative analysis of gastrin mRNA and peptide in normal and cancerous human pancreas. Int J Mol Med 1998; 2: 309-15.
101. Rehfeld JF, Bardram L, Hilsted L. Gasttrin in human bronchogenic carcinomas: constant expression but variable processing of progastrin. Cancer Res 1989; 49: 2840-3.
102. Caplin M, Savage K, Khan K et al. Expression and processing of gastrin in pancreatic adenocarcinoma. Br J Surg 2000; 87: 1035-41.
103. Brett B, Savage K, Michaeli D et al. The effect of antibodies raised against gastrimmune on the proliferation of human pancreatic carcinoma cell lines. Gut 1999; 44(SI): A48.
104. Gilliam AD, Henwood M, Watson SA et al. G17DT - a study to determine the safety, tolerance and antibody response in patients with advanced pancreatic carcinoma. Gastroenterology 2001; 120: 1350.
105. Gilliam AD, Henwood M, Watson SA et al. G17DT therapy may improve the survival of patients with advanced pancreatic carcinoma. J Clin Oncol 2001; 20: 533.